RANI THERAPEUTICS HOLDINGS INC. - CLASS A COMMON
2.5700
12-November-24 16:45:00
15 minutes delayed
Stocks
-0.0500
-1.91%
Today's range
2.5500 - 2.6700
ISIN
N/A
Source
NASDAQ
-
12 Oct 2023 16:05:00 By Nasdaq GlobeNewswire
-
18 Sep 2023 08:00:00 By Nasdaq GlobeNewswire
-
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
07 Sep 2023 16:05:00 By Nasdaq GlobeNewswire
-
Rani Therapeutics to Participate in September Investor Conferences
06 Sep 2023 08:00:00 By Nasdaq GlobeNewswire
-
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
11 Aug 2023 16:05:00 By Nasdaq GlobeNewswire
-
Rani Therapeutics to Participate in August Investor Conferences
04 Aug 2023 16:05:00 By Nasdaq GlobeNewswire
-
21 Jun 2023 08:00:01 By Nasdaq GlobeNewswire
-
08 Jun 2023 08:00:00 By Nasdaq GlobeNewswire
-
Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105
05 Jun 2023 08:00:02 By Nasdaq GlobeNewswire
-
Rani Therapeutics to Present at the Jefferies Healthcare Conference
01 Jun 2023 08:00:01 By Nasdaq GlobeNewswire
-
31 May 2023 08:00:01 By Nasdaq GlobeNewswire
-
Rani Therapeutics Appoints Kate McKinley as Chief Business Officer
24 May 2023 08:00:02 By Nasdaq GlobeNewswire
-
Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update
10 May 2023 16:05:01 By Nasdaq GlobeNewswire
-
Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
25 Apr 2023 08:00:01 By Nasdaq GlobeNewswire
-
Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
11 Apr 2023 08:00:01 By Nasdaq GlobeNewswire
-
22 Mar 2023 16:05:00 By Nasdaq GlobeNewswire
-
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
16 Mar 2023 16:05:00 By Nasdaq GlobeNewswire
-
Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment
09 Jan 2023 08:30:00 By Nasdaq GlobeNewswire
-
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update
05 Jan 2023 16:05:00 By Nasdaq GlobeNewswire
-
Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study
06 Dec 2022 16:05:00 By Nasdaq GlobeNewswire